AXS-05 FDA Approval Status
FDA Approved: No
Brand name: AXS-05
Generic name: dextromethorphan and bupropion
Company: Axsome Therapeutics
Treatment for: Major Depressive Disorder
AXS-05 (dextromethorphan and bupropion) is an investigational NMDA receptor antagonist with multimodal activity in development for the treatment of major depressive disorder and other central nervous system (CNS) disorders.
- The dextromethorphan component of AXS-05 is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist (also known as a glutamate receptor modulator) and a sigma-1 receptor agonist.
- The bupropion component of AXS-05 is a norepinephrine and dopamine reuptake inhibitor and serves to increase the bioavailability of dextromethorphan.
Development Timeline for AXS-05
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.